In the mazdutide trials, the most common adverse events were gastrointestinal: nausea, diarrhea, and vomiting, along with reduced appetite. They were generally mild to moderate and tended to track the dose, showing up most during escalation and at the higher 9 mg arm.[1][2]
Reviewed for accuracy · Last reviewed July 8, 2026Because mazdutide is investigational outside China, its longer-term safety profile beyond the trial windows is not yet well characterized, and much of the human data comes from Chinese populations. The hedged reading is that the short-term profile looks similar in character to other incretin peptides, with the gastrointestinal effects concentrated around dose increases.
Reduced appetite is expected from the GLP-1 activity; the glucagon component is proposed to add energy-expenditure and liver-fat effects, but the human data cannot cleanly separate appetite-dependent from appetite-independent contributions.
Many people find gastrointestinal effects ease as the body adjusts to a dose. Holding a dose steady before the next step-up and injecting after a lighter meal are commonly discussed ways to limit nausea.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.